Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

Euro Surveill. 2021 Mar;26(12):2100329. doi: 10.2807/1560-7917.ES.2021.26.12.2100329.ABSTRACTSera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom's approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.PMID:33769252 | PMC:PMC7995559 | DOI:10.2807/1560-7917.ES.2021.26.12.2100329

Source: Euro Surveill - March 26, 2021 Category: Infectious Diseases Authors: Sathyavani Subbarao Lenesha A Warrener Katja Hoschler Keith R Perry Justin Shute Heather Whitaker Michelle O'Brien Frances Baawuah Paul Moss Helen Parry Shamez N Ladhani Mary E Ramsay Kevin E Brown Gayatri Amirthalingam Source Type: research